Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05349916 · ClinicalTrials.gov registry record · NA

The Attenuating Effect of Soluble Fiber Consumption on Postprandial Glycemia in Humans

A NA study of Type 2 Diabetes and Blood Sugar; High, sponsored by Purdue University.

Completed
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT05349916: Completed NA study of Type 2 Diabetes and Blood Sugar; High, sponsored by Purdue University.

NCT05349916 is a NA study of Type 2 Diabetes and Blood Sugar; High that has completed, run by Purdue University. The registered enrollment target is 24 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05349916, a NA study of Type 2 Diabetes and Blood Sugar; High, has completed, sponsored by Purdue University.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The main objective of the current study is to investigate whether consumption of soluble fibers (isomaltodextrin \[IMD\], partially digestible maltodextrin) and RS4 starch will lower postprandial glycemia as well as postprandial insulin in human subjects with relatively high fasting blood glucose, when consumed with a specific amount of digestible carbohydrate (rice porridge). The primary outcome of the study is the effect of fibers on postprandial blood glucose, whereas the secondary outcome will be its effect on postprandial blood insulin.

Primary Outcome

Blood glucose will be measured, (AUC)

Interventions

  • OTHER Control
  • OTHER Isomaltodextrin Low Dose
  • OTHER Isomaltodextrin High Dose
  • OTHER GPC partially digestible maltodextrin
  • OTHER Resistant Starch Type 4

Study Locations (1)

Indiana

  • Purdue University - West Lafayette

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2021-12-07
Est. Completion 2022-03-09
Phase NA
Purdue University

141 total trials

What the finished NCT05349916 record still lists

NCT05349916 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 5 interventions - of which Control is the first listed.

NCT05349916 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT05349916 about?

NCT05349916 is a clinical study titled "The Attenuating Effect of Soluble Fiber Consumption on Postprandial Glycemia in Humans". The main objective of the current study is to investigate whether consumption of soluble fibers (isomaltodextrin \[IMD\], partially digestible maltodextrin) and RS4 starch will lower postprandial glycemia as well as postprandial insulin in human subjects with relatively high fasting blood glucose, w...

What is the current status of trial NCT05349916?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2021-12-07. Estimated completion is 2022-03-09.

What conditions does trial NCT05349916 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Blood Sugar; High, Postprandial Hyperglycemia.

What interventions are being tested in trial NCT05349916?

The interventions under investigation include: Control (OTHER), Isomaltodextrin Low Dose (OTHER), Isomaltodextrin High Dose (OTHER), GPC partially digestible maltodextrin (OTHER), Resistant Starch Type 4 (OTHER).

Who is sponsoring clinical trial NCT05349916?

This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05349916 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05349916's enrollment target sits among peer trials

24 279th of 327 higher than 45 of 327 other Type 2 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05349916, the US trial registry maintained by the National Library of Medicine. NCT05349916 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.